[go: up one dir, main page]

BR0110732A - Inibidores de aromatase e anticorpos anti-her2 monoclonais como agente antitumor - Google Patents

Inibidores de aromatase e anticorpos anti-her2 monoclonais como agente antitumor

Info

Publication number
BR0110732A
BR0110732A BR0110732-1A BR0110732A BR0110732A BR 0110732 A BR0110732 A BR 0110732A BR 0110732 A BR0110732 A BR 0110732A BR 0110732 A BR0110732 A BR 0110732A
Authority
BR
Brazil
Prior art keywords
monoclonal anti
antitumor agent
aromatase inhibitors
her2 antibodies
her2
Prior art date
Application number
BR0110732-1A
Other languages
English (en)
Inventor
Giorgio Massimini
Gabriela Piscitelli
Dinesh Purandare
Original Assignee
Pharmacia Italia Spa
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Upjohn Co filed Critical Pharmacia Italia Spa
Publication of BR0110732A publication Critical patent/BR0110732A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"INIBIDORES DE AROMATASE E ANTICORPOS ANTI-HER2 MONOCLONAIS COMO AGENTE ANTITUMOR". Um método de tratar um ser humano que sofre de um distúrbio dependente de hormónio caracterizado pela expressão em excesso de HER2 compreendendo administrar ao referido ser humano um inibidor de aromatase, por exemplo exemestano, fadrozol, letrozol e anastrozol e um anticorpo contra HER2 por exemplo trastuzumab, em quantidades eficazes para produzir um efeito terapêutico sinérgico ou superaditivo.
BR0110732-1A 2000-05-15 2001-04-19 Inibidores de aromatase e anticorpos anti-her2 monoclonais como agente antitumor BR0110732A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (en) 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents

Publications (1)

Publication Number Publication Date
BR0110732A true BR0110732A (pt) 2003-02-04

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110732-1A BR0110732A (pt) 2000-05-15 2001-04-19 Inibidores de aromatase e anticorpos anti-her2 monoclonais como agente antitumor

Country Status (20)

Country Link
EP (1) EP1282440A1 (pt)
JP (1) JP2003533490A (pt)
KR (1) KR20030014223A (pt)
CN (1) CN1429118A (pt)
AU (1) AU784617B2 (pt)
BR (1) BR0110732A (pt)
CA (1) CA2409652A1 (pt)
CZ (1) CZ20023748A3 (pt)
EA (1) EA005931B1 (pt)
EE (1) EE200200622A (pt)
HK (1) HK1054200A1 (pt)
HU (1) HUP0301877A2 (pt)
IL (1) IL152389A0 (pt)
MX (1) MXPA02011194A (pt)
NO (1) NO20025302L (pt)
NZ (1) NZ523004A (pt)
PL (1) PL360153A1 (pt)
SK (1) SK16022002A3 (pt)
WO (1) WO2001087334A1 (pt)
ZA (1) ZA200209815B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
KR20080038458A (ko) 2000-05-19 2008-05-06 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
EP1377298B1 (en) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane for treating hormono-dependent disorders
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
CN100424175C (zh) 2002-03-26 2008-10-08 上海泽生科技开发有限公司 ErbB-3 用于肿瘤治疗的方法和组合物
JP2005534679A (ja) * 2002-07-01 2005-11-17 サビエント ファーマシューティカルズ，インコーポレイティド 治療的処置のための組成物および方法
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
EP3195879A1 (en) 2005-02-23 2017-07-26 Genentech, Inc. Extending time to disease progression or survival in cancer patients
WO2007045027A1 (en) * 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
CA2784211C (en) 2010-02-18 2019-12-24 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102068429B (zh) * 2010-12-28 2011-12-14 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
WO2013081645A2 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
WO2016061615A1 (en) 2014-10-22 2016-04-28 Chavah Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
EP3364978A4 (en) 2015-10-22 2019-06-05 Havah Therapeutics Pty Ltd METHOD FOR REDUCING MAMMOGRAPHIC BREAST DENSITY AND / OR BREAST CANCER RISK
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
JP2022535827A (ja) 2019-06-03 2022-08-10 ハバ セラピューティクス ピーティワイ エルティディ アンドロゲン剤およびアロマターゼ阻害剤の送達のための医薬製剤およびシステム、ならびに使用のための方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Also Published As

Publication number Publication date
NZ523004A (en) 2004-09-24
EE200200622A (et) 2004-06-15
CA2409652A1 (en) 2001-11-22
EP1282440A1 (en) 2003-02-12
MXPA02011194A (es) 2003-03-10
KR20030014223A (ko) 2003-02-15
SK16022002A3 (sk) 2003-04-01
ZA200209815B (en) 2003-12-03
AU784617B2 (en) 2006-05-18
HK1054200A1 (zh) 2003-11-21
CZ20023748A3 (cs) 2003-04-16
CN1429118A (zh) 2003-07-09
AU5630901A (en) 2001-11-26
EA200201213A1 (ru) 2003-04-24
HUP0301877A2 (hu) 2003-09-29
PL360153A1 (en) 2004-09-06
JP2003533490A (ja) 2003-11-11
EA005931B1 (ru) 2005-08-25
WO2001087334A1 (en) 2001-11-22
NO20025302D0 (no) 2002-11-05
NO20025302L (no) 2002-11-05
IL152389A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
BR0110732A (pt) Inibidores de aromatase e anticorpos anti-her2 monoclonais como agente antitumor
UA94899C2 (ru) Фиксированное дозирование антител к her
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
MXPA02010059A (es) Metodo para administrar un anticuerpo.
MY155603A (en) Notch-binding agents and antagonists and methods of use thereof
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
WO2019160751A3 (en) Methods for treating cancer with anti-pd-1 antibodies
TW200505481A (en) Compositions and methods for treating coagulation related disorders
NO20041598L (no) Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er)
EA200870141A1 (ru) Комбинационная терапия с использованием антител к egfr и her2
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
BRPI0511187A (pt) método para tratar cáncer em um indivìduo
MX2024015058A (es) Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
MX2023001481A (es) Metodos para tratar pacientes con hipercolesterolemia refractaria.
MY124799A (en) Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
MX2023003723A (es) Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
MX2022014586A (es) Métodos y composiciones para tratar la fuga vascular.
MX2020011341A (es) Una composicion para el tratamiento de una o mas enfermedades relacionadas con los estrogenos.
WO2002011705A3 (en) Composition for combined use of aromatase inhibitors
WO2023056355A3 (en) Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.